Jun Zhang

Associate Professor

University of Kansas Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jun Zhang is an Associate Professor at the University of Kansas Medical Center, USA. His research focuses on oncology, specifically the molecular and clinical characterization of various cancers including non-small-cell lung cancer and colorectal cancer. Recent articles highlight his work on novel therapies and clinical trials aimed at improving treatment outcomes for patients with complex solid tumors.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Christine Bestvina

Assistant Professor

University of Chicago Medicine

UNITED STATES

View details

Gregory Gan

Assistant Professor

University of Kansas Medical Center

UNITED STATES

View details

Fengting Yan

National Cancer Institute

UNITED STATES

View details

Luciano Mutti

UNITED STATES

View details

Cuncong Zhong

University of Kansas

UNITED STATES

View details

Robert B. Cameron

Chief, Thoracic Surgery

VA Greater Los Angeles Healthcare System

UNITED STATES

View details

Amin Nassar

Yale University

UNITED STATES

View details

Justin Chau

Clinical Assistant Professor, Oncology

University of Iowa Hospitals and Clinics

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jun Zhang

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid Tumors.

Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS G12C mutant non-small-cell lung cancer.

Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

Real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in HER2-overexpressing malignancies: A single-center retrospective study.

Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma.

Preliminary report of the TUMORIN Trial (using ex vivo tumoroids to predict immunotherapy response in NSCLC)

Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer.

A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors

Patient Preferences for EGFR Exon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.

Phase II dose expansion study of DSP107, a first-in-class fusion protein targeting CD47 and 4-1BB, in combination with atezolizumab in patients with advanced MSS colorectal cancer

Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies.

Leveraging gut metagenomic k-mer signature for the development of a practical and robust model to predict immunotherapy response in NSCLC

Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.

Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma.

Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in preliminary clinical analyses

Editorial: Prognostic factors in non-small cell lung cancer.

Integrated de novo gene prediction and peptide assembly of metagenomic sequencing data.

Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.

The Microbiome-TIME Axis: A Host of Possibilities.

Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial

AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)

Collaborators (8)

Christine Bestvina

Gregory Gan

Fengting Yan

Luciano Mutti

Cuncong Zhong

Robert B. Cameron

Amin Nassar

Justin Chau

Make your next move.